Evidence map›Paper›PMID 41816737›Full record

ArticleTurkish journal of medical sciences2026

Fitness cost and biofilm formation in fosfomycin-resistant clinical

Mustafa Ökeer, Sabire Şöhret Aydemir, Bayrı Eraç

Abstract read
In one paragraph

Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mustafa ÖkeerDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Ege University, İzmir, Turkiye.ORCID https://orcid.org/0000-0003-2869-7025
Sabire Şöhret AydemirDepartment of Medical Microbiology, Faculty of Medicine, Ege University, İzmir, Turkiye.ORCID https://orcid.org/0000-0001-8354-9100
Bayrı EraçDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Ege University, İzmir, Turkiye.ORCID https://orcid.org/0000-0002-6343-2519

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Fosfomycin has regained importance owing to its unique mechanism of action and effectiveness against extended-spectrum β-lactamase-producing Gram-negative bacteria. This study aimed to evaluate the biological fitness cost associated with fosfomycin resistance and its impact on biofilm formation in clinical Materials and methods: A total of 78 Results: Of the 78 Conclusion: These findings suggest that, in the examined isolates, decreased susceptibility to fosfomycin was associated with slower growth, whereas biofilm formation ability remained largely unaffected. Continued surveillance of fosfomycin resistance is essential owing to its potential implications for bacterial fitness and pathogenicity.

Indexed as

Anti-Bacterial AgentsBiofilmsDrug Resistance, BacterialEscherichia coliFosfomycinKlebsiella pneumoniaeHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsFosfomycinbiofilmEscherichia colifitness costFosfomycinKlebsiella pneumoniaevirulence

Identifiers

PMID41816737
PMCPMC12974299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.